Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC
NCT04833257
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
63
Enrollment
OTHER
Sponsor class
Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG:
GP combine with Tislelizumab neoadjuvant therapy+CCRT
Sponsor
Sun Yat-sen University